• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

水泡性口炎病毒-肿瘤选择性复制与蛋白质翻译

VSV-tumor selective replication and protein translation.

作者信息

Barber Glen N

机构信息

Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, FL 33136, USA.

出版信息

Oncogene. 2005 Nov 21;24(52):7710-9. doi: 10.1038/sj.onc.1209042.

DOI:10.1038/sj.onc.1209042
PMID:16299531
Abstract

The emergence of vesicular stomatatis virus (VSV) as a potent antitumor agent has made a dissection of the molecular determinants of host-cell permissiveness to this virus an important objective. Such insight would not only enable the intelligent design of future generations of recombinant VSV vectors to combat disease, but may also resolve general features of cellular transformation that may be exploited by this virus, and perhaps other oncolytic viruses. The defective pathways underlining the oncolytic activity of VSV remain to be fully determined but recent data indicates that flaws in innate immune responses, involving the interferon (IFN) system, may commonly occur in tumor cells and thus play a large role in facilitating oncolysis. Aside from the IFN system, however, it is almost certain that other key cellular pathways may be similarly defective and therefore cooperatively contribute towards mediating rapid oncolytic virus activity. Recent data have indicated that defects in cancer cell translational regulation could be one area that may be exploited by VSV. Certainly, all viruses require cellular protein synthesis pathways to facilitate their replication and many have devised numerous mechanisms to ensure that viral mRNAs become translated at the expense of the host. Using VSV as a model, this review will discuss some of the recent developments in the fields of innate immunity and translational regulation that may help explain mechanisms of viral oncolysis.

摘要

水疱性口炎病毒(VSV)作为一种有效的抗肿瘤药物的出现,使得剖析宿主细胞对该病毒易感性的分子决定因素成为一个重要目标。这样的见解不仅能够为未来几代用于对抗疾病的重组VSV载体进行智能设计,还可能揭示该病毒以及或许其他溶瘤病毒可能利用的细胞转化的一般特征。VSV溶瘤活性背后的缺陷途径仍有待完全确定,但最近的数据表明,涉及干扰素(IFN)系统的先天免疫反应缺陷可能在肿瘤细胞中普遍存在,因此在促进溶瘤过程中起很大作用。然而,除了IFN系统之外,几乎可以肯定其他关键的细胞途径可能同样存在缺陷,因此协同促进快速的溶瘤病毒活性。最近的数据表明,癌细胞翻译调控缺陷可能是VSV可以利用的一个领域。当然,所有病毒都需要细胞蛋白质合成途径来促进其复制,并且许多病毒已经设计出多种机制来确保病毒mRNA得以翻译,而以宿主为代价。以VSV为模型,本综述将讨论先天免疫和翻译调控领域的一些最新进展,这些进展可能有助于解释病毒溶瘤的机制。

相似文献

1
VSV-tumor selective replication and protein translation.水泡性口炎病毒-肿瘤选择性复制与蛋白质翻译
Oncogene. 2005 Nov 21;24(52):7710-9. doi: 10.1038/sj.onc.1209042.
2
Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.溶瘤性水疱性口炎病毒是用于高危膀胱癌膀胱内治疗的有效药物。
Cancer Res. 2008 Jun 15;68(12):4506-10. doi: 10.1158/0008-5472.CAN-08-0238.
3
Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses.前列腺肿瘤对野生型和M蛋白突变型水疱性口炎病毒的敏感性。
Virology. 2004 Dec 5;330(1):34-49. doi: 10.1016/j.virol.2004.08.039.
4
To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control.复制还是不复制:通过翻译控制实现溶瘤病毒在癌细胞中的选择性复制。
Oncogene. 2005 Nov 21;24(52):7697-709. doi: 10.1038/sj.onc.1209053.
5
Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.β干扰素和α2a干扰素对头部和颈部癌细胞免受水疱性口炎病毒诱导的肿瘤溶解具有不同的保护作用。
J Virol. 2015 Aug;89(15):7944-54. doi: 10.1128/JVI.00757-15. Epub 2015 May 20.
6
Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats.溶瘤性水疱性口炎病毒用于治疗免疫健全大鼠的原位肝细胞癌。
Cancer Res. 2003 Jul 1;63(13):3605-11.
7
VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.用于癌症治疗的基于莫洛尼鼠白血病病毒(MuLV)的水疱性口炎病毒糖蛋白(VSV-G)假型化、半复制能力的逆转录病毒。
Gene Ther. 2006 Oct;13(20):1457-70. doi: 10.1038/sj.gt.3302782. Epub 2006 May 25.
8
Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.实验进化产生新型溶瘤单纯疱疹病毒,改善了对病毒耐药的胰腺癌细胞中的复制。
J Virol. 2020 Jan 17;94(3). doi: 10.1128/JVI.01643-19.
9
Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer.解除呼肠孤病毒溶瘤、Ras信号传导、翻译控制与癌症之间的联系。
Oncogene. 2005 Nov 21;24(52):7720-8. doi: 10.1038/sj.onc.1209041.
10
Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.胰腺癌对溶瘤单纯疱疹病毒的耐药性:I 型干扰素信号的作用。
Virology. 2013 Feb 5;436(1):221-34. doi: 10.1016/j.virol.2012.11.014. Epub 2012 Dec 14.

引用本文的文献

1
Mechanism of action of over-expressing NY-ESO-1 in vesicular stomatitis virus and its combination therapy with NY-ESO-1 TCR-T.水泡性口炎病毒中过表达NY-ESO-1的作用机制及其与NY-ESO-1 TCR-T的联合治疗
Front Immunol. 2025 Aug 12;16:1617941. doi: 10.3389/fimmu.2025.1617941. eCollection 2025.
2
Advances in Oncolytic Viral Therapy in Melanoma: A Comprehensive Review.溶瘤病毒疗法在黑色素瘤治疗中的进展:全面综述
Vaccines (Basel). 2025 Jul 3;13(7):727. doi: 10.3390/vaccines13070727.
3
Oncolytic virotherapy for hepatocellular carcinoma: A potent immunotherapeutic landscape.
用于肝细胞癌的溶瘤病毒疗法:一种强大的免疫治疗前景。
World J Gastrointest Oncol. 2024 Jul 15;16(7):2867-2876. doi: 10.4251/wjgo.v16.i7.2867.
4
Negative-Strand RNA Virus-Vectored Vaccines.负链RNA病毒载体疫苗
Methods Mol Biol. 2024;2786:51-87. doi: 10.1007/978-1-0716-3770-8_3.
5
Construction of VSVΔ51M oncolytic virus expressing human interleukin-12.表达人白细胞介素-12的水疱性口炎病毒Δ51M溶瘤病毒的构建
Front Mol Biosci. 2023 May 15;10:1190669. doi: 10.3389/fmolb.2023.1190669. eCollection 2023.
6
Oncolytic viruses: A novel treatment strategy for breast cancer.溶瘤病毒:一种治疗乳腺癌的新策略。
Genes Dis. 2021 Dec 16;10(2):430-446. doi: 10.1016/j.gendis.2021.11.011. eCollection 2023 Mar.
7
Regulated control of virus replication by 4-hydroxytamoxifen-induced splicing.4-羟基他莫昔芬诱导剪接对病毒复制的调控
Front Microbiol. 2023 Mar 13;14:1112580. doi: 10.3389/fmicb.2023.1112580. eCollection 2023.
8
Single-step rapid chromatographic purification and characterization of clinical stage oncolytic VSV-GP.临床阶段溶瘤性水疱性口炎病毒糖蛋白(VSV-GP)的一步快速色谱纯化及特性分析
Front Bioeng Biotechnol. 2022 Oct 28;10:992069. doi: 10.3389/fbioe.2022.992069. eCollection 2022.
9
The gamble between oncolytic virus therapy and IFN.溶瘤病毒治疗与 IFN 的博弈。
Front Immunol. 2022 Aug 25;13:971674. doi: 10.3389/fimmu.2022.971674. eCollection 2022.
10
Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?基于重组水疱性口炎病毒的免疫病毒疗法:我们在哪里?
Front Immunol. 2022 Jun 28;13:898631. doi: 10.3389/fimmu.2022.898631. eCollection 2022.